New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity (CELC), a clinical-stage biotechnology company, has quietly surged more than 215% year-to-date, turning heads on ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

Find out how to take Fulvestrant(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

The median time to treatment failure was 17.6 months in the fulvestrant arm and 12.7 months in the anastrozole arm, representing an HR of 0.73 (95% CI, 0.54-1.00).